Literature DB >> 31070201

A spermine-conjugated lipophilic Pt(iv) prodrug designed to eliminate cancer stem cells in ovarian cancer.

Morgan Stilgenbauer1, Amarasooriya M D S Jayawardhana1, Payel Datta1, Zhizhou Yue1, Michael Gray1, Frederick Nielsen1, David J Bowers1, Haihua Xiao2, Yao-Rong Zheng1.   

Abstract

We developed a spermine-conjugated lipophilic Pt(iv) prodrug that is able to reduce the cancer stem cell population in ovarian cancer. The therapeutic effect is attributed to the hydrophobic tail and cationic spermine head group, the combination of which allows the Pt(iv) prodrug to localize in mitochondria and induce corresponding damage.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31070201     DOI： 10.1039/c9cc02081k

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  4 in total

1.  Interactions between mitochondria-damaging platinum(IV) prodrugs and cytochrome c.

Authors:  Amarasooriya M D S Jayawardhana; Yao-Rong Zheng
Journal:  Dalton Trans       Date:  2022-02-01       Impact factor: 4.390

2.  Nanoparticle BAF312@CaP-NP Overcomes Sphingosine-1-Phosphate Receptor-1-Mediated Chemoresistance Through Inhibiting S1PR1/P-STAT3 Axis in Ovarian Carcinoma.

Authors:  Ke Gong; Yang Dong; Liting Wang; Yi Duan; Jian Yu; Ying Sun; Min Bai; Yourong Duan
Journal:  Int J Nanomedicine       Date:  2020-08-04

Review 3.  Recent Advances in the Chemistry of Metal Carbamates.

Authors:  Giulio Bresciani; Lorenzo Biancalana; Guido Pampaloni; Fabio Marchetti
Journal:  Molecules       Date:  2020-08-07       Impact factor: 4.411

Review 4.  Cancer stem cells and strategies for targeted drug delivery.

Authors:  Jin Cao; Shubhmita Bhatnagar; Jiawei Wang; Xueyong Qi; Swayam Prabha; Jayanth Panyam
Journal:  Drug Deliv Transl Res       Date:  2020-10-23       Impact factor: 5.671
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.